New research has demonstrated the possibility of HIV vaccines

The Duke Health Group described the development pathways for HIV-protected antibodies as well as synthetic viruses that mimic the HIV surface structure and it induces HIV antibodies through vaccines. At present, the purpose of the HIV vaccine is to extensively induce neutralizing antibodies, one of which is to develop part of the antibody that can recognize the HIV surface structure, and our research through recombinant rat proteins demonstrates this possibility.

Researchers have found that the immune system of the infected people responds to the virus through the cooperation efforts between the b cell lineages, thus GF-induced neutralizing antibodies. The antibody development process involves a rare activity of the genetically-modified protective antibody.

Immunogen imitates and neutralizes antibodies and immune attacks in the exact location, and synthetic immunogen can find this exact location. In the process of testing primates, synthesis of immunogen can induce antibodies into this critical area.

"We have found weaknesses in the surface structure of HIV, and not just a place but a few. Thus, the effective vaccine can target at least one weakness so that the immune system is armed to deal with the mutation which is going to happen," the researchers said.

The complete study was published in the journal Science Translational Medicine. Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. We provide good-quality recombinant proteins like recombinant COLEC12 at competitive prices.